ストックスクリーナーアプリを入手
37.06
5.76%
2.02
アフターアワーズ：
37.06
前日終値:
$35.04
開ける：
$35.05
24時間の取引高:
588.33K
Relative Volume:
1.64
時価総額：
$1.68B
収益：
-
当期純損益:
$-161.15M
株価収益率:
-9.976
EPS:
-3.7149
ネットキャッシュフロー:
$-138.61M
1週間 パフォーマンス:
+3.40%
1か月 パフォーマンス:
+32.31%
6か月 パフォーマンス:
+130.76%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$34.31
$37.27
1週間の範囲:
$33.92
$37.61
52週間の値動き範囲:
$12.24
$37.61
Maplight Therapeutics Inc Stock (MPLT) Company Profile
名前
Maplight Therapeutics Inc
セクター
電話
650-839-4360
住所
800 CHESAPEAKE DRIVE, REDWOOD CITY
Compare MPLT vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
37.06 | 1.59B | 0 | -161.15M | -138.61M | -3.7149 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-08 | 開始されました | Needham | Buy |
| 2026-04-07 | 開始されました | TD Cowen | Buy |
| 2026-03-19 | 開始されました | Canaccord Genuity | Buy |
| 2025-11-21 | 開始されました | Jefferies | Buy |
| 2025-11-21 | 開始されました | Leerink Partners | Outperform |
| 2025-11-21 | 開始されました | Morgan Stanley | Overweight |
| 2025-11-21 | 開始されました | Stifel | Buy |
すべてを表示
Maplight Therapeutics Inc (MPLT) 最新ニュース
MPLTMapLight Therapeutics Inc Options - Finviz
MapLight Therapeutics autism drug shows mixed potential in adolescents - MSN
Analyst Maintains Buy on MapLight Therapeutics, Reaffirms $45 Price Target Ahead of Key Phase 2 ZEPHYR Readout - TipRanks
Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout? - Yahoo Finance
Number of shareholders of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Price to book forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Price to earnings forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Enterprise value to EBITDA forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Price to sales forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT - TradingView
Raymond James Initiates MapLight Therapeutics(MPLT.US) With Buy Rating, Announces Target Price $46 - Moomoo
Maplight Therapeutics (MPLT) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
MPLT Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 MapLight Therapeutics Inc For: 25 June By Investing.com - Investing.com South Africa
MapLight Therapeutics, Inc. Actuals & Estimates (NASDAQ:MPLT) - TradingView
Tonix, MapLight are new strong buys at Raymond James on upcoming catalysts - MSN
MapLight Therapeutics: The Cobenfy Challenger Does Not Look Like A Bargain (NASDAQ:MPLT) - Seeking Alpha
Tonix, MapLight are new Strong Buys at Raymond James on upcoming catalysts - Seeking Alpha
MPLT Initiated Coverage On by Raymond James -- Strong Buy Rating - GuruFocus
MapLight Therapeutics Initiated at Strong Buy by Raymond James - Moomoo
Raymond James initiates MapLight stock with strong buy on drug trial - Investing.com Canada
MapLight Therapeutics, Inc. 2026 Annual Meeting Results and Company Information – SEC 8-K Filing Summary - Minichart
MapLight Therapeutics appoints two directors to board - Investing.com
MapLight Therapeutics appoints two directors to board By Investing.com - Investing.com India
MapLight Shareholders Back Board Slate and Auditor - TipRanks
MapLight Therapeutics Announces Changes to Board of Directors - The Manila Times
MapLight Therapeutics Appointed Martin Babler, Troy Cox to Bd >MPLT - Moomoo
MPLT Maintained by Craig-Hallum -- Price Target Lowered to $40 - GuruFocus
Analyst Maintains Buy/Outperform on ML-004’s Safety, Irritability Signal and Pipeline Strength; Price Target Steady at $45 - TipRanks
Overweight Rating Reaffirmed on ML004’s Irritability Efficacy and Safety Profile; $34 Price Target Maintained - TipRanks
MapLight Therapeutics stock maintained at Buy by H.C. Wainwright - Investing.com Australia
MPLT Maintained by Needham -- Price Target Raised to $42.00 - GuruFocus
Why is MapLight Therapeutics stock rallying today? - Investing.com
MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents - Sahm
Form 144 MAPLIGHT THERAPEUTICS For: 10 February - Investing.com
MapLight reports Phase 2 autism trial results for ML-004 - grafa.com
Why is MapLight Therapeutics stock rallying today? By Investing.com - Investing.com Canada
Form 8K MapLight Therapeutics Inc For: 22 June - Investing.com UK
MapLight Reports Phase 2 Data for Autism Candidate - TipRanks
MapLight’s autism drug trial misses primary endpoint By Investing.com - Investing.com Australia
H.C. Wainwright reiterates MapLight Therapeutics stock rating on muscarinic mechanism potential - Investing.com Canada
MapLight Therapeutics' Phase 2 Trial of ML-004 in Autism Spectrum Disorder Fails to Meet Primary Endpoint - Moomoo
MapLight’s autism drug trial misses primary endpoint - Investing.com
Form 8K MapLight Therapeutics Inc For: 22 June By Investing.com - Investing.com South Africa
Strong adolescent irritability signal in MapLight (MPLT) ML-004 Phase 2 IRIS trial - Stock Titan
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder - The Manila Times
MapLight Therapeutics, Inc.(NasdaqGS:MPLT) added to S&P Biotechnology Select Industry Index - marketscreener.com
Maplight Therapeutics Inc (MPLT) 財務データ
収益
当期純利益
現金流量
EPS
Maplight Therapeutics Inc (MPLT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hanson Kristopher | General Counsel |
May 11 '26 |
Sale |
30.13 |
13,917 |
419,263 |
162,331 |
| Kroeger Christopher A. | Chief Executive Officer |
May 08 '26 |
Sale |
27.69 |
34,411 |
952,835 |
1,526,309 |
| Kroeger Christopher A. | Chief Executive Officer |
May 07 '26 |
Sale |
28.65 |
20,100 |
575,797 |
1,560,720 |
| Kroeger Christopher A. | Chief Executive Officer |
May 11 '26 |
Sale |
30.11 |
13,980 |
421,002 |
1,512,329 |
| Foff Erin Pennock | Chief Medical Officer |
May 07 '26 |
Sale |
28.54 |
4,438 |
126,640 |
346,059 |
| Lillie James Woodruff | Chief Scientific Officer |
May 07 '26 |
Sale |
28.28 |
721 |
20,390 |
242,729 |
| Setia Vishwas | Chief Financial Officer |
May 04 '26 |
Sale |
28.11 |
14,904 |
418,930 |
377,723 |
| Setia Vishwas | Chief Financial Officer |
May 05 '26 |
Sale |
28.20 |
10,903 |
307,444 |
366,820 |
| Setia Vishwas | Chief Financial Officer |
May 06 '26 |
Sale |
28.24 |
10,564 |
298,345 |
356,256 |
| Foff Erin Pennock | Chief Medical Officer |
May 06 '26 |
Sale |
28.76 |
24,052 |
691,749 |
350,497 |
1.18%
2.48%
大文字化:
|
ボリューム (24 時間):